Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.11 - $134.19
Previous CloseN/A
Volume140.83K
Average Volume (3M)1.10M
Market Cap
$6.21B
Enterprise Value$4.19B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 12, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.00
Shares Outstanding48,765,404
10 Day Avg. Volume1,363,805
30 Day Avg. Volume1,104,438
Standard Deviation0.22
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.34
Price to Cash Flow (P/CF)-83.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.14
Enterprise Value/Ebitda-13.94
Forecast
1Y Price Target
$165.47Price Target Upside28.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Commercial SuccessRecent progress underscores commercial success with multiple marketed products.
Patent SettlementA patent settlement with Teva Pharmaceuticals locks in exclusivity for Auvelity until 2038-2039, delaying any generic version and securing market presence.
Sales GrowthApproximately 158K prescriptions were written for Axsome's flagship antidepressant product AUVELITY™, representing an increase of 87% vs. the year-ago period.
Bears Say
Financial PerformanceThe EPS of -$1.54 was ~50% lower than consensus of -$0.99, mainly driven by higher than expected expenses.
Investor ExpectationsWeakness in the stock is a reflection of the stock recent move following the Auvelity IP settlement and low investor expectations ahead of the 1Q Ph 3 data readouts for solriamfetol in ADHD and MDD.
Market CompetitionIn the ADHD market, peak sales expectations for solriamfetol are conservative due to competition from highly effective generic stimulants.
---
Ownership Overview
1.42% Insiders
19.18% Mutual Funds
35.65% Other Institutional Investors
30.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $64.11 and its highest was $134.19 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $6.21B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is May 12, 2025 which is in 80 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Feb 18, 2025. The company reported -$1.54 earnings per share for the quarter, missing the consensus estimate of -$1.001 by -$0.539.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -1.23.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 48,765,404 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.54 in its last earnings report, missing expectations of -$1.001. Following the earnings report the stock price went down -2.333%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in AXSM
---
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$165.47 (28.17% Upside)
$165.47 (28.17% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.79%
12-Months-Change
Fundamentals
Return on Equity
-231.63%
Trailing 12-Months
Asset Growth
-3.36%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
AXSM Company Deck
---
AXSM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Axsome Therapeutics showed strong revenue growth and significant progress in its product pipeline, including new product approvals. However, the company continued to face high net losses and operating expenses, along with challenges in market access and pricing pressures. The overall sentiment of the call is optimistic about future growth, yet tempered by these financial challenges.Read More>---
AXSM Stock 12 Month Forecast
Average Price Target
$165.47
▲(28.17% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Prothena
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Best Analysts Covering AXSM
1 Year
1 Year Success Rate
14/15 ratings generated profit
1 Year Average Return
+22.88%
reiterated a buy rating 2 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +22.88% per trade.
---